Evaluation of high dose atorvastatin therapy 24 hours before elective percutaneous coronary intervention on peri-PCI myocardial infarction

Percutaneous coronary intervention (PCI) may been associated with high-er risk of cardiac events during this procedure. The goal of this study was to compare high dose atorvastatin therapy with low dose atorvastatin therapy 24 hours before PCI to a reduction in Peri- percutaneous coronary intervention myocardial infarction. One hundred ninety patients with stable angina were enrolled in a randomiz-ed controlled clinical trial study. All patients received low dose atorvastatin. The patients scheduled for elective PCI were randomized to atorvastatin (80 mg/d، n=95) or placebo (n=95) within 24 hours before the procedure. Creatine kinase-MB، troponin I، and high sensitive C- reactive protein levels were measured at baseline and at 6 and 12 hours after the procedure. PCI related myocardial infarction was defined as increasing of Creatine kinase-MB or troponin I three times compared with values before procedure. Myocardial infarction was detected after coronary intervention in 4. 2% of patients in the atorvastatin group and in 13. 7% of those in the placebo group (P=0. 022). Mean of changed levels of Creatine kinase-MB (0. 7±0. 5 versus 3. 3±1. 9 ng/mL، P<0. 001)، troponin I (0. 1±0. 2 versus 0. 4±0. 7 ng/mL، P=0. 052) and hs-CRP (0. 1±0. 5 versus 1±0. 9 ng/mL، P<0. 001) were significantly lower in the statin than in the placebo group. Pretreatment with high dose atorvastatin within 24 hours before elective percutaneous coronary intervention significantly reduces procedural myocardial infarct-tion in elective coronary intervention.